Tango Therapeutics (TNGX) Amortizatization of Intangibles (2020 - 2026)
Tango Therapeutics (TNGX) recorded quarterly Amortizatization of Intangibles of $972000.0 in Q1 2026, up 226.56% quarter-over-quarter from -$768000.0 in Q4 2025, and down 3.95% on a YoY basis from $1.0 million in Q1 2025.
Tango Therapeutics (TNGX) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Tango Therapeutics' Amortizatization of Intangibles history runs 7 years deep, the most recent figure standing at $972000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 3.95% year-over-year to $972000.0; the TTM figure through Mar 2026 stood at -$2.7 million (down 22.11% YoY), while the FY2025 annual figure was -$2.7 million, up 41.78% from the prior year.
- Amortizatization of Intangibles was $972000.0 for Q1 2026 at Tango Therapeutics, up from -$768000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $3.2 million in Q2 2024 to a low of -$7.4 million in Q4 2024.
- Historically, Amortizatization of Intangibles has averaged -$18058.8 across 5 years, with a median of $877000.0 in 2023.
- Biggest YoY gain for Amortizatization of Intangibles was 256.31% in 2024; the steepest drop was 910.5% in 2024.
- A 5-year view of Amortizatization of Intangibles shows it stood at $882000.0 in 2022, then grew by 3.63% to $914000.0 in 2023, then plunged by 910.5% to -$7.4 million in 2024, then surged by 89.63% to -$768000.0 in 2025, then soared by 226.56% to $972000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $972000.0 (Q1 2026), -$768000.0 (Q4 2025), and -$560000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Tango Therapeutics | 4.05 Bn | 3.67 Bn | - | 972,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 972,000.00 |
| Mar 31, 2026 | 972,000.00 |
| Dec 31, 2025 | -768,000.00 |
| Dec 31, 2025 | -768,000.00 |
| Sep 30, 2025 | -560,000.00 |
| Sep 30, 2025 | -560,000.00 |
| Jun 30, 2025 | -2.37 Mn |
| Jun 30, 2025 | -2.37 Mn |
| Mar 31, 2025 | 1.01 Mn |
| Mar 31, 2025 | 1.01 Mn |
| Dec 31, 2024 | -7.41 Mn |
| Dec 31, 2024 | -7.41 Mn |
| Sep 30, 2024 | 941,000.00 |
| Sep 30, 2024 | 941,000.00 |
| Jun 30, 2024 | 3.22 Mn |
| Jun 30, 2024 | 3.22 Mn |
| Mar 31, 2024 | -1.37 Mn |
| Mar 31, 2024 | -1.37 Mn |
| Dec 31, 2023 | 914,000.00 |
| Dec 31, 2023 | 914,000.00 |